Evaluates efficacy of ultrafine water clusters in reducing erythema from laser treatment, suggesting therapeutic benefits.
Post-procedural erythema following energy-based dermatological treatments is a common concern affecting patient satisfaction and downtime. Nano-sized ultrafine water clusters (UFW), generated by conductive polymer poly(3,4-ethylenedioxythiophene)-poly(styrene sulfonate) (PEDOT/PSS) technology, represent a nanometer-scale water cluster species (average aerosol-phase particle diameter ≈ 1.4 nm). This split-face, randomized, evaluator-blinded pilot study evaluated the efficacy of UFW in reducing erythema following fractionated picosecond alexandrite laser (Fr-PSAL) treatment with a diffractive lens array. Twenty-five female subjects were assigned to a pre-treatment (n = 13) or post-treatment (n = 12) group. UFW was applied for 30 min to one randomly selected facial side; the contralateral side served as control. Two independent board-certified dermatologists, blinded to allocation, correctly identified the UFW-treated side with high concordance in both groups. In the post-treatment group, each evaluator achieved 11/12 correct identifications (91.7%, binomial p = 0.003); Cohen's kappa between evaluators was 0.625 (substantial agreement). In the pre-treatment group, Evaluator 1 identified 11/13 correct (84.6%, p = 0.011) and Evaluator 2 identified 12/13 correct (92.3%, p = 0.002); Cohen's kappa was 0.831 (almost perfect agreement). An exploratory semi-quantitative hemoglobin-enhanced image analysis provided objective support, although the strength of that support differed between the two groups. In the post-treatment group, the pre-specified primary metric (erythema density) was robustly significant (Cohen's d = - 0.93, p = 0.004). In the pre-treatment group, the pre-specified primary metric (erythema area) was also significant (d = - 0.57, p = 0.031), but this prophylactic-arm result depended on per-subject selection of the comparison timepoint and was not significant when a fixed 6 h timepoint was used (7/13 correct, 53.8%; p = 0.448); it should therefore be regarded as hypothesis-generating. No adverse events were observed. These results provide the first clinical evidence that UFW effectively reduces post-laser erythema, with findings consistent with both therapeutic and prophylactic mechanisms of action.
No takes yet. Share an insight, caveat, or question.
Kentaro Oku (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: